RecruitingAtherosclerosisCardiovascular DiseaseObesity

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Eligible age

18+ yrs

Accepts

All genders

Locations

18 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased risk for cardiovascular event. Participation in the study will last about 9 months.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ hsCRP ≥2 mg/L and ≤15 mg/L at screening
✓ At least one of the following chronic conditions:
✓ Established atherosclerotic cardiovascular disease (ASCVD)
✓ Obesity (body mass index (BMI) ≥30 kg/m2)
✓ Type 2 diabetes
✓ Hypertension
✓ Chronic kidney disease Grade 3 or 4

You may not qualify if…

✕ Acute cardiovascular event within 60 days prior to screening
✕ Acute decompensated heart failure hospitalization within 60 days prior to screening
✕ Planned coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or major surgery at the time of randomization
✕ New York Heart Association Class III or IV heart failure
✕ Uncontrolled hypertension at screening (systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg)
✕ Type 1 diabetes
✕ Type 2 diabetes with Hemoglobin A1c ≥9.0% (86 mmol/mol) at screening
✕ Nephrotic syndrome, estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m², or history of kidney transplant